Emerging Trends to Reshape the Pneumococcal Vaccine Market: Breakthrough In Vaccine For Enhanced Adult Protection as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Pneumococcal Vaccine Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for the pneumococcal vaccine has shown a significant increase in the past few years. The forward projection indicates growth from $8.94 billion in 2024 to $9.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.2%. Factors contributing to growth during the historic period include the discovery of streptococcus pneumoniae, issues of public health, initiatives for early vaccination, advancements in healthcare, and alterations in vaccine policy.

Pneumococcal Vaccine Market Size Forecast: What's the Projected Valuation by 2029?
Over the next several years, a robust growth is expected in the pneumococcal vaccine market size. It's projected to reach $12.12 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.3%. The projected growth in the forecast period is primarily due to evolving pneumococcal strains, ongoing research and development efforts, immunization efforts, wider vaccine accessibility, and an ageing population. The key trends during the forecast period will be the development of multivalent vaccines, vaccinating at-risk populations, enhancing vaccine effectiveness, conducting education and awareness campaigns, and focusing on infant immunization.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What Are the Drivers Transforming the Pneumococcal Vaccine Market?
The escalating incidence of pneumococcal infections is poised to fuel the expansion of the pneumococcal vaccine market. Pneumococcal infection, typically caused by the bacteria Streptococcus Pneumoniae or pneumococcus, often results in conditions such as pneumonia, bloodstream infections, and infections of the ear and sinuses. The pneumococcal vaccine works by inciting the body to generate antibodies against pneumococcal bacteria. These antibodies help to minimize or eradicate disease-carrying bacteria and toxins, thus safeguarding children, the elderly, and individuals with compromised immune systems from various types of pneumococcal diseases. For example, as reported by the US-based public health agency, the Center for Disease Control and Prevention, in January 2022, Pneumococcal pneumonia is responsible for approximately 150,000 hospital admissions annually in the US, making up as much as 30% of adult community-acquired pneumonia cases. Consequently, the rising incidence of pneumococcal infections is propelling the growth of the pneumococcal vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Long-Term Trends Will Define the Future of the Pneumococcal Vaccine Market?
In an effort to boost their market profitability, leading firms in the pneumococcal vaccine market are working on product innovation. For example, the U.S.-based pharmaceutical corporation, Merck & Co Inc., unveiled the V116 vaccine in July 2023. The purpose of V116 is to focus on the eight unique serotypes of Streptococcus pneumoniae that are mainly accountable for adult pneumococcal disease. Compared to its counterparts, V116 has demonstrated a superior immunogenicity across several serotypes in adults and has also elicited positive immune reactions in both individuals who have never been vaccinated and those who have been previously vaccinated. V116 is currently in Phase 3 development and has been recognized as a breakthrough therapy by the U.S. Food and Drug Administration (FDA).

Which Segments in the Pneumococcal Vaccine Market Offer the Most Profit Potential?
The pneumococcal vaccine market covered in this report is segmented -

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous
3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
4) By End User: Pediatrics, Adults

Subsegments:
1) By Prevnar 13: Pediatric Formulation, Adult Formulation
2) By Synflorix: Pediatric Formulation, Adult Formulation
3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes
4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Which Firms Dominate the Pneumococcal Vaccine Market by Market Share and Revenue in 2025?
Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Which Regions Offer the Highest Growth Potential in the Pneumococcal Vaccine Market?
North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.